Workflow
15位基金经理晋级“百亿操盘手”
21世纪经济报道·2025-09-23 13:59

Core Viewpoint - The article highlights the significant growth in the number of active equity fund managers in the A-share market, with 15 new managers surpassing 10 billion yuan in assets under management in the first half of 2025, driven by strong performance and market conditions [1][3]. Group 1: Fund Manager Growth - As of the end of Q2 2025, there are 84 active equity fund managers managing over 10 billion yuan, an increase of 15 from the end of 2024 [1][3]. - The new managers come from 11 different public fund institutions, with notable contributions from China Europe Fund, Huatai-PB Fund, and Yongying Fund [1][3]. - The management scale of these new managers has increased by over 100%, indicating strong performance and investor confidence [1][3]. Group 2: Performance Metrics - A total of 77 active equity funds achieved returns exceeding 100% year-to-date, while 1,167 funds returned between 50% and 100% [3]. - The major indices, including CSI 300 and ChiNext 50, saw increases of 14.94% and 53.13%, respectively, highlighting a favorable market environment for active equity funds [3]. Group 3: Individual Fund Manager Performance - The top three fund managers by management scale are Zhang Wei from Huatai-PB (16.764 billion yuan), Yan Siqian from Penghua (16.136 billion yuan), and Lan Xiaokang from China Europe (15.558 billion yuan) [4][6]. - Significant growth rates were observed, with Zhang Lu and Gao Nan from Yongying achieving increases of 761.20% and 337.03%, respectively [7][6]. - Other managers like Guo Jie from E Fund and Chen Yanzhong from GF Fund also reported substantial growth, with increases of 198.47% and 239.96% [7][6]. Group 4: Investment Strategies - The newly promoted fund managers are focusing on sectors such as robotics, pharmaceuticals, and domestic consumption, reflecting a trend towards innovation and growth [10][12]. - Zhang Lu emphasizes the importance of core robotics companies and government support for the industry, while Zhang Wei is focusing on innovative pharmaceutical companies with global competitiveness [10][12]. - Blue Xiaokang highlights opportunities in both traditional industries and new production capabilities, suggesting a balanced approach to investment across various sectors [12].